Category Archives: Nano Medicine

Ok-Hyeon Kim,1 Jun Hyung Park,2 Jong In Son,1 Kyung-Yong Kim,1 Hyun Jung Lee1,2

1Department of Anatomy and Cell Biology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea; 2Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea

Correspondence: Hyun Jung LeeChung-Ang University, Rm615 Bd105, 84 Heuksuk-Ro, Dongjak-gu, Seoul 06974, Republic of KoreaTel +82-2-820-5434Email pluto38@cau.ac.kr

Purpose: Although single-walled nanotubes (SWNTs) with functional groups have been suggested as a potential nanomedicine to treat neuronal disorders, effective routes to administer SWNTs have not been compared thus far. The bloodbrain barrier is a considerable challenge for the development of brain-targeting drugs, and therefore functionalized SWNT routes of administration have been needed for testing Parkinsons disease (PD) treatment. Here, effective administration routes of functionalized SWNTs were evaluated in PD mouse model.Methods: Three different administration routes were tested in PD mouse model. Functionalized SWNTs were injected directly into the lateral ventricle three days before (Method 1) or after (Method 2) 6-hydroxydopamine (6-OHDA) injection to compare the protective effects of SWNTs against dopaminergic neuronal death or functionalized SWNTs were injected intravenously at three and four days after 6-OHDA injection (Method 3). Asymmetric behaviors and histological assessment from all animals were performed at two weeks after 6-OHDA injection.Results: Ventricular injections of SWNTs both before or after 6-OHDA exposure protected dopaminergic neurons both in the substantia nigra and striatum and alleviated rotational asymmetry behavior in PD mice. Moreover, intravenous administration of SWNTs three and four days after 6-OHDA injection also prevented neuronal death and PD mice behavioral impairment without apparent cytotoxicity after six months post-treatment.Conclusion: Our study demonstrates that functionalized SWNTs could effectively protect dopaminergic neurons through all administration routes examined herein. Therefore, SWNTs are promising nanomedicine agents by themselves or as therapeutic carriers to treat neuronal disorders such as PD.

Keywords: single-walled nanotubes, Parkinsons disease, intracranial, intravenous, nanomedicine

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Go here to see the original:
Both Intracranial and Intravenous Administration of Functionalized Car | IJN - Dove Medical Press

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that clinical results from studies spanning the Companys dermatologic application portfolio will be presented at the American Society for Dermatologic Surgery (ASDS) virtual annual meeting on October 9-11, 2020. Positive study results generated using the Companys innovative cellular-specific Nano-Pulse Stimulation mechanism performed with its CellFX System for the treatment of sebaceous hyperplasia lesions, cutaneous non-genital warts, plantar warts, and basal cell carcinoma will be presented in two oral presentations and two e-posters.

These newest published results from NPS clinical studies provide further evidence of the unique CellFX cellular mechanism of action for multiple applications across the lesion treatment spectrum. These recent findings were also the basis for the recently initiated multicenter clinical study to compare NPS technology to RF electrodessication in clearing sebaceous hyperplasia lesions. Treatment of the first study patient was previously announced by the Company on October 1, 2020.

The positive results being shared at this years ASDS meeting add to the growing body of evidence in support of using Nano-Pulse Stimulation technology delivered by the CellFX System to treat a broad range of dermatology applications for which targeted clearance of cellular lesions or structures is medically or cosmetically desirable, said Darrin Uecker, President and CEO of Pulse Biosciences. These data underscore our persistent dedication to providing dermatologists a highly differentiated non-thermal solution with vast opportunity.

Highlights from this meeting of leading dermatologic surgeons demonstrate:

Dr. Ted Lain, author of the non-genital cutaneous wart study, said: We are pleased to present conclusive evidence of consistently high rates of clearance across a variety of anatomical areas in one to two NPS treatments. Compared to todays standard wart treatments, which typically require two to four visits to clear common cutaneous warts, these NPS results represent a much more convenient approach for the patient and the physician. Dr. Lain is Chief Medical Officer of Sanova Dermatology in Austin, TX.

Members of the dermatologic surgery community who have registered for the virtual meeting can gain access to accepted video presentations and posters at the ASDS meeting portal. The listed dates and times below are subject to change.

Title

A Prospective, Non-Randomized, Multicenter Pivotal Study of Nano-Pulse Stimulation (NPS) for Treatment of Cutaneous Non-Genital Warts

Chief Medical Officer of Sanova Dermatology, Austin, TX

(narrated video slide set)

Friday, October 9th at

11:15am ET

General Derm Track

Nano-Pulse Stimulation (NPS) Procedure to Treat Sebaceous Hyperplasia A Dose-Ranging, Multi-Center, Pivotal Study

Medical Director of Dermatology, Laser & Vein Specialists of the Carolinas, Charlotte, NC.

(narrated video slide set)

Saturday, October 10th at

11:00 to 11:45am ET

Cosmetic Track

A Prospective, Non-Randomized, Multicenter Pivotal Study of Nano-Pulse Stimulation (NPS) Technology for Cutaneous Warts on the Feet

Clear Dermatology& Aesthetics Center, Scottsdale, AZ

A first human feasibility study of Nano-Pulse Stimulation (NPS) to evaluate the potential elimination of a biopsy-confirmed nodular or superficial BCC in a short-term treat and resect study design

Mohs surgeon and founder of Surgical Dermatology Group, Birmingham, AL

We are thrilled to showcase our latest research and congratulate the American Society for Dermatology Surgery for hosting this important scientific exchange with aesthetic and surgical dermatology professionals as we work toward commercial introduction of our CellFX System powered by Nano-Pulse Stimulation technology, said Ed Ebbers, Pulses Executive Vice President and General Manager, Dermatology.

About Pulse Biosciences

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX System will be the first commercial product to harness the distinctive advantages of the Companys proprietary Nano-Pulse Stimulation (NPS) technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more please visit http://www.pulsebiosciences.com.

Caution: Pulse Biosciences CellFX System and Nano-Pulse Stimulation technology are for investigational use only.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences expectations regarding regulatory clearance and the timing of FDA and other regulatory filings or approvals, including meetings with FDA and the ability of the Company to successfully complete a 510(k) submission for the CellFX System or for a specific indication for the treatment of sebaceous hyperplasia (SH) lesions, the ability of the Company to prepare and provide data to FDA and other regulatory bodies, NPS technology including the effectiveness of such technology and the effectiveness of related clinical studies in predicting outcomes resulting from the use of NPS technology, the CellFX System including the benefits of the CellFX System and commercialization of the CellFX System, current and planned future clinical studies and the ability of the Company to execute such studies and results of any such studies, other matters related to its pipeline of product candidates, the Companys market opportunity and commercialization plans, including the market for the treatment of SH, future financial performance, the impact of COVID-19 and other future events. These statements are not historical facts but rather are based on Pulse Biosciences current expectations, estimates, and projections regarding Pulse Biosciences business, operations and other similar or related factors. Words such as may, will, could, would, should, anticipate, predict, potential, continue, expects, intends, plans, projects, believes, estimates, and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Continued here:
Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American...

LOS ANGELES, United States: QY Research has recently published a research report titled, Global and China Healthcare Nanotechnology (Nanomedicine) Market Size, Status and Forecast 2020-2026. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Healthcare Nanotechnology (Nanomedicine) market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Healthcare Nanotechnology (Nanomedicine) market.

The report includes CAGR, market shares, sales, gross margin, value, volume, and other vital market figures that give an exact picture of the growth of the global Healthcare Nanotechnology (Nanomedicine) market.

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Healthcare Nanotechnology (Nanomedicine) market.

Key questions answered in the report:

TOC

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Healthcare Nanotechnology (Nanomedicine) Market Size Growth Rate by Type: 2020 VS 20261.2.2 Nanomedicine1.2.3 Nano Medical Devices1.2.4 Nano Diagnosis1.2.5 Other1.3 Market by Application1.3.1 Global Healthcare Nanotechnology (Nanomedicine) Market Share by Application: 2020 VS 20261.3.2 Anticancer1.3.3 CNS Product1.3.4 Anti-infective1.3.5 Other1.4 Study Objectives1.5 Years Considered 2 Global Growth Trends2.1 Global Healthcare Nanotechnology (Nanomedicine) Market Perspective (2015-2026)2.2 Global Healthcare Nanotechnology (Nanomedicine) Growth Trends by Regions2.2.1 Healthcare Nanotechnology (Nanomedicine) Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Healthcare Nanotechnology (Nanomedicine) Historic Market Share by Regions (2015-2020)2.2.3 Healthcare Nanotechnology (Nanomedicine) Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top Healthcare Nanotechnology (Nanomedicine) Players by Market Size3.1.1 Global Top Healthcare Nanotechnology (Nanomedicine) Players by Revenue (2015-2020)3.1.2 Global Healthcare Nanotechnology (Nanomedicine) Revenue Market Share by Players (2015-2020)3.2 Global Healthcare Nanotechnology (Nanomedicine) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by Healthcare Nanotechnology (Nanomedicine) Revenue3.4 Global Healthcare Nanotechnology (Nanomedicine) Market Concentration Ratio3.4.1 Global Healthcare Nanotechnology (Nanomedicine) Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by Healthcare Nanotechnology (Nanomedicine) Revenue in 20193.5 Key Players Healthcare Nanotechnology (Nanomedicine) Area Served3.6 Key Players Healthcare Nanotechnology (Nanomedicine) Product Solution and Service3.7 Date of Enter into Healthcare Nanotechnology (Nanomedicine) Market3.8 Mergers & Acquisitions, Expansion Plans 4 Healthcare Nanotechnology (Nanomedicine) Breakdown Data by Type (2015-2026)4.1 Global Healthcare Nanotechnology (Nanomedicine) Historic Market Size by Type (2015-2020)4.2 Global Healthcare Nanotechnology (Nanomedicine) Forecasted Market Size by Type (2021-2026) 5 Healthcare Nanotechnology (Nanomedicine) Breakdown Data by Application (2015-2026)5.1 Global Healthcare Nanotechnology (Nanomedicine) Historic Market Size by Application (2015-2020)5.2 Global Healthcare Nanotechnology (Nanomedicine) Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Healthcare Nanotechnology (Nanomedicine) Market Size (2015-2026)6.2 North America Healthcare Nanotechnology (Nanomedicine) Market Size by Type (2015-2020)6.3 North America Healthcare Nanotechnology (Nanomedicine) Market Size by Application (2015-2020)6.4 North America Healthcare Nanotechnology (Nanomedicine) Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe Healthcare Nanotechnology (Nanomedicine) Market Size (2015-2026)7.2 Europe Healthcare Nanotechnology (Nanomedicine) Market Size by Type (2015-2020)7.3 Europe Healthcare Nanotechnology (Nanomedicine) Market Size by Application (2015-2020)7.4 Europe Healthcare Nanotechnology (Nanomedicine) Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China Healthcare Nanotechnology (Nanomedicine) Market Size (2015-2026)8.2 China Healthcare Nanotechnology (Nanomedicine) Market Size by Type (2015-2020)8.3 China Healthcare Nanotechnology (Nanomedicine) Market Size by Application (2015-2020)8.4 China Healthcare Nanotechnology (Nanomedicine) Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan Healthcare Nanotechnology (Nanomedicine) Market Size (2015-2026)9.2 Japan Healthcare Nanotechnology (Nanomedicine) Market Size by Type (2015-2020)9.3 Japan Healthcare Nanotechnology (Nanomedicine) Market Size by Application (2015-2020)9.4 Japan Healthcare Nanotechnology (Nanomedicine) Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 Southeast Asia10.1 Southeast Asia Healthcare Nanotechnology (Nanomedicine) Market Size (2015-2026)10.2 Southeast Asia Healthcare Nanotechnology (Nanomedicine) Market Size by Type (2015-2020)10.3 Southeast Asia Healthcare Nanotechnology (Nanomedicine) Market Size by Application (2015-2020)10.4 Southeast Asia Healthcare Nanotechnology (Nanomedicine) Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11 Key Players Profiles11.1 Amgen11.1.1 Amgen Company Details11.1.2 Amgen Business Overview11.1.3 Amgen Healthcare Nanotechnology (Nanomedicine) Introduction11.1.4 Amgen Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020))11.1.5 Amgen Recent Development11.2 Teva Pharmaceuticals11.2.1 Teva Pharmaceuticals Company Details11.2.2 Teva Pharmaceuticals Business Overview11.2.3 Teva Pharmaceuticals Healthcare Nanotechnology (Nanomedicine) Introduction11.2.4 Teva Pharmaceuticals Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)11.2.5 Teva Pharmaceuticals Recent Development11.3 Abbott11.3.1 Abbott Company Details11.3.2 Abbott Business Overview11.3.3 Abbott Healthcare Nanotechnology (Nanomedicine) Introduction11.3.4 Abbott Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)11.3.5 Abbott Recent Development11.4 UCB11.4.1 UCB Company Details11.4.2 UCB Business Overview11.4.3 UCB Healthcare Nanotechnology (Nanomedicine) Introduction11.4.4 UCB Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)11.4.5 UCB Recent Development11.5 Roche11.5.1 Roche Company Details11.5.2 Roche Business Overview11.5.3 Roche Healthcare Nanotechnology (Nanomedicine) Introduction11.5.4 Roche Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)11.5.5 Roche Recent Development11.6 Celgene11.6.1 Celgene Company Details11.6.2 Celgene Business Overview11.6.3 Celgene Healthcare Nanotechnology (Nanomedicine) Introduction11.6.4 Celgene Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)11.6.5 Celgene Recent Development11.7 Sanofi11.7.1 Sanofi Company Details11.7.2 Sanofi Business Overview11.7.3 Sanofi Healthcare Nanotechnology (Nanomedicine) Introduction11.7.4 Sanofi Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)11.7.5 Sanofi Recent Development11.8 Merck & Co11.8.1 Merck & Co Company Details11.8.2 Merck & Co Business Overview11.8.3 Merck & Co Healthcare Nanotechnology (Nanomedicine) Introduction11.8.4 Merck & Co Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)11.8.5 Merck & Co Recent Development11.9 Biogen11.9.1 Biogen Company Details11.9.2 Biogen Business Overview11.9.3 Biogen Healthcare Nanotechnology (Nanomedicine) Introduction11.9.4 Biogen Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)11.9.5 Biogen Recent Development11.10 Stryker11.10.1 Stryker Company Details11.10.2 Stryker Business Overview11.10.3 Stryker Healthcare Nanotechnology (Nanomedicine) Introduction11.10.4 Stryker Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)11.10.5 Stryker Recent Development11.11 Gilead Sciences10.11.1 Gilead Sciences Company Details10.11.2 Gilead Sciences Business Overview10.11.3 Gilead Sciences Healthcare Nanotechnology (Nanomedicine) Introduction10.11.4 Gilead Sciences Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.11.5 Gilead Sciences Recent Development11.12 Pfizer10.12.1 Pfizer Company Details10.12.2 Pfizer Business Overview10.12.3 Pfizer Healthcare Nanotechnology (Nanomedicine) Introduction10.12.4 Pfizer Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.12.5 Pfizer Recent Development11.13 3M Company10.13.1 3M Company Company Details10.13.2 3M Company Business Overview10.13.3 3M Company Healthcare Nanotechnology (Nanomedicine) Introduction10.13.4 3M Company Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.13.5 3M Company Recent Development11.14 Johnson & Johnson10.14.1 Johnson & Johnson Company Details10.14.2 Johnson & Johnson Business Overview10.14.3 Johnson & Johnson Healthcare Nanotechnology (Nanomedicine) Introduction10.14.4 Johnson & Johnson Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.14.5 Johnson & Johnson Recent Development11.15 SmitH& Nephew10.15.1 SmitH& Nephew Company Details10.15.2 SmitH& Nephew Business Overview10.15.3 SmitH& Nephew Healthcare Nanotechnology (Nanomedicine) Introduction10.15.4 SmitH& Nephew Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.15.5 SmitH& Nephew Recent Development11.16 Leadiant Biosciences10.16.1 Leadiant Biosciences Company Details10.16.2 Leadiant Biosciences Business Overview10.16.3 Leadiant Biosciences Healthcare Nanotechnology (Nanomedicine) Introduction10.16.4 Leadiant Biosciences Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.16.5 Leadiant Biosciences Recent Development11.17 Kyowa Hakko Kirin10.17.1 Kyowa Hakko Kirin Company Details10.17.2 Kyowa Hakko Kirin Business Overview10.17.3 Kyowa Hakko Kirin Healthcare Nanotechnology (Nanomedicine) Introduction10.17.4 Kyowa Hakko Kirin Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.17.5 Kyowa Hakko Kirin Recent Development11.18 Takeda10.18.1 Takeda Company Details10.18.2 Takeda Business Overview10.18.3 Takeda Healthcare Nanotechnology (Nanomedicine) Introduction10.18.4 Takeda Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.18.5 Takeda Recent Development11.19 Ipsen10.19.1 Ipsen Company Details10.19.2 Ipsen Business Overview10.19.3 Ipsen Healthcare Nanotechnology (Nanomedicine) Introduction10.19.4 Ipsen Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.19.5 Ipsen Recent Development11.20 Endo International10.20.1 Endo International Company Details10.20.2 Endo International Business Overview10.20.3 Endo International Healthcare Nanotechnology (Nanomedicine) Introduction10.20.4 Endo International Revenue in Healthcare Nanotechnology (Nanomedicine) Business (2015-2020)10.20.5 Endo International Recent Development 12 Analysts Viewpoints/Conclusions 13 Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original:
Healthcare Nanotechnology (Nanomedicine) Market size is projected to reach US$ 372870 million by 2026, from US$ 215130 million in 2020, at a CAGR of...

TipRanks

Is it time for the bears to break out the champagne glasses? Not so fast, says Goldman Sachs. Volatility has ruled the Street for the last few weeks, leading some to conclude that those with a more pessimistic outlook had been vindicated, but the firm believes stocks can still climb higher.According to Goldman Sachs head of U.S. equity strategy, David Kostin, the S&P 500 could still hit 3,600 by the end of the year, and 3,800 by mid-2021, on the back of vaccine-related optimism and progress with the economic reopening. This would reflect gains of 10% and 16%, respectively, should the index ultimately reach these targets.Despite the sharp sell-off in the past week, we remain optimistic about the path of the U.S. equity market in coming months. The Superforecaster probability of a mass-distributed vaccine by Q1 2021 has surged to nearly 70% and economic data show a continuing recovery, Kostin wrote in a recent note. On top of this, the strategist argues the vaccines arrival will push U.S. GDP growth to 6%, compared to the 3.9% consensus estimate.Given Kostins outlook, we wanted to check out three stocks scoring major praise from Goldman Sachs. Not only have they been given a Buy rating, but the firms analysts also see at least 50% upside potential on tap for each. Using TipRanks database, we found out that all three tickers have gotten a thumbs up from analysts at other firms as well. Let's take a closer look.Intellia Therapeutics (NTLA)Focused on utilizing gene editing to develop cell therapies, Intellia Therapeutics wants to stomp out cancer and other immunological diseases for good. Based on its innovative technology, Goldman Sachs recommends that investors pull the trigger.Representing the firm, 5-star analyst Salveen Richter believes that what makes NTLA a stand-out is its use of an adaptive gene editing system based on a proprietary lipid nanoparticle (LNP) delivery method of CRISPR/Cas9 to leverage multiple gene editing strategies. These include the generation of knock-outs (KO) for toxic genes, restoring functional genes by inserting new DNA sequences and the use of consecutive editing combining KO and insertion approaches.We are positive on NTLAs in vivo gene editing approach as it offers a modular system with CRISPR/Cas9 gene editing for functionally curative outcomes. While we note the initial focus is on delivery to the liver, extrahepatic tissue targeting (i.e. CNS) could expand the breadth of NTLAs platform. NTLA is also leveraging its CRISPR/Cas9 editing tools ex vivo to create next-generation engineered cells that can treat oncological and immunological diseases, Richter explained.To this end, the analyst sees several potential catalysts on tap for the next year. Proof-of-concept data for lead program NTLA-2001, its therapy targeting transthyretin amyloidosis (ATTR), a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues, could come by mid-2021. This data stands to inform the drugs clinical profile (safety/tolerability and early signs of sustained TTR knockdown), which would de-risk NTLAs in vivo editing platform, in Richters opinion.On top of this, IND-enabling studies for NTLA-2002, its therapy designed for hereditary angioedema (HAE), and NTLA-5001, its therapy for WT1+ acute myeloid leukemia (AML), are set to kick off in 2021. Richter estimates that peak sales for both candidates could reach $895 million and $806 million, respectively, with data from both also validating the breadth of editing approaches (knockouts and/or insertions).If that wasnt enough, Richter cites the ongoing NVS-led Phase 1/2 OTQ923 sickle cell disease (SCD) trial as a possible upside driver. While we note the limited economics to NTLA from this program and competitor dynamics with bluebird bios (BLUE) LentiGlobin and CRISPR Therapeutics (CRSP) CTX001 that are ahead in clinical development, the study should serve as proof-of-concept for the platform. First data could be presented in 2021, the analyst commented.All of this prompted Richer to initiate coverage with a Buy rating and $33 price target. This target conveys her confidence in NTLAs ability to climb 50% higher in the next year. (To watch Richters track record, click here)Looking at the consensus breakdown, 3 Buys and 2 Holds have been published in the last three months. Therefore, NTLA gets a Moderate Buy consensus rating. Based on the $37.13 average price target, shares could rise 67% in the next year. (See NTLA stock analysis on TipRanks)Vir Biotechnology (VIR)Moving on to another healthcare company, Vir Biotechnology is developing a broad portfolio of product candidates that are designed to combat serious, global infectious diseases in new ways. With it standing at the front of the pack in the COVID-19 monoclonal antibody (mAb) race, its no wonder Goldman Sachs likes what its seeing.Firm analyst Paul Choi cites a recent data readout from one of VIRs competitors as reaffirming his confidence. On September 16, Eli Lilly reported interim data from the Phase 2 BLAZE-1 trial evaluating its mAb therapies, LY-CoV555 and LY-CoV016, in mild or moderate COVID-19 patients. The data revealed that treatment with LY-CoV555 led to a roughly 72% reduction in the need for hospitalization, with no safety signals observed.Choi also points out that the results were more pronounced in high risk patients (age or BMI) as most study hospitalizations across both groups occurred in patients with these underlying risk factors.While resistant viral variants did appear in 8% of LY-CoV555-treated patients and 6% of patients on placebo, management has stated that competing single or multiple mAb cocktail approaches might not be optimized, with viral escape mutants potentially emerging. VIR argues its approach is differentiated given the high barrier to resistance, potent effector function, potential for increased lung tissue concentration and extended half-life.Even though VIR is behind its peers in terms of development timelines, Choi thinks that the company is making substantial progress. VIR recently initiated the Phase 2/3 COMET-ICE study of VIR-7831, its mAb for COVID-19, as a monotherapy (versus a combination approach) in patients with mild or moderate COVID-19. Initial data is set to be released by the end of 2020, with top-line data expected in January. Weighing in on the above, Choi commented, In the absence of preclinical binding affinity data from LY-CoV555, it is premature to hypothesize on the potential for VIR-7831 to demonstrate improved efficacy vs. the competing antibodies; however, we see the LLY data as establishing proof-of-concept for antibodies in COVID-19 while also setting an attainable bar for future antibody monotherapy/cocktail treatments. Moreover, we view the addressable market for COVID-19 antibodies as significant enough to support several approved therapies in the indication in the near-term.In line with his optimistic approach, Choi reiterated his Buy rating and $54 price target. Should the 5-star analysts thesis play out, a twelve-month gain of 69% could potentially be in the cards. (To watch Chois track record, click here)Is the rest of the Street in agreement? The majority of other analysts are. 4 Buys, 1 Hold and 1 Sell have been issued in the last three months, so the word on the Street is that VIR is a Moderate Buy. With the average price target clocking in at $51.67, shares could jump 61% in the next year. (See VIR stock analysis on TipRanks)Peloton Interactive (PTON)Switching gears now, we move on to Peloton Interactive. The company, which offers exercise bikes and remote workout classes, rose to fame at the start of the COVID-19 pandemic. After its fiscal Q4 earnings results blew estimates out of the water, Goldman Sachs believes this stock has more room to run.In the most recent quarter, PTON posted revenue of $607.1 million, beating the $586.2 million consensus estimate and reflecting a 172% year-over-year increase. This is up from growth of 65.6% in the previous quarter. Adjusted EBITDA came in at $143.6 million, ahead of the Streets $73.5 million call. Management pointed to heightened demand during the COVID-19 crisis and significantly lower marketing spend as the drivers of this strong showing.Goldman Sachs Heath Terry tells clients he was especially excited about the Connected Fitness segments performance. Connected Fitness product revenue landed at $486 million, up 199% year-over-year, while customer deposits and deferred revenue grew 300% year-over-year. The five-star analyst also highlights the fact that subscriber net adds were 205,000, versus 174,100 net adds in fiscal Q3 2020 and guidance of 154-164,000.As for PTONs forward-looking guidance, Terry was also impressed. While the company guided fiscal Q1 2021 and FY21 revenue and adjusted EBITDA well above consensus, given the backlog of demand exiting the June quarter and the 6-8 weeks of deliveries already on order by consumers, we expect this guidance will again prove overly conservative, he explained.This performance prompted Terry to state, We continue to believe that Peloton represents a significant long-term opportunity as the company is in the earliest stages of creating new and expanding existing categories of connected fitness products, an opportunity that we believe has been permanently accelerated by the current COVID-19 crisis.It should be noted that the company faces significant risks going forward. These include new entrants, evolving consumer tastes as well as execution challenges. That being said, Terrys bullish thesis remains very much intact.Expounding on this, the analyst said, ... we believe that the window of opportunity for any meaningful competitor is rapidly closing, something that, along with the large and expanding addressable market for Pelotons high ARPU, high margin, extremely low churn subscription business, remains underappreciated by the market, even with the stocks recent outperformance.It should come as no surprise, then, that Terry stayed with the bulls. To this end, he kept a Buy rating and $138 price target on the stock. Investors could be pocketing a gain of 53%, should this target be met in the twelve months ahead. (To watch Terrys track record, click here)In general, other analysts are on the same page. PTONs Strong Buy consensus rating breaks down into 20 Buys, 2 Holds and 1 Sell. The $112.05 average price target brings the upside potential to 23%. (See PTON stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Originally posted here:
Cend Therapeutics Announces Acquisition of Impilo Therapeutics - Yahoo Finance

From applying leeches in medieval times to the development of nanotechnology in the modern world, we have come a long way. Lets take a look at this guide and follow the new healthcare industry trends about technology. For more info, you can check out metime.com.

In the medical industry, tech is associated with multiple radical changes. People can handle the COVID situation better because of the presence of tech in the healthcare setup. Here are some of the most widely recognized and used tech changes in the Health sector:

With telemedicine, you can receive medical attention via various communication modes, including audio or video calls. You can now connect to the best healthcare professional from any part of the globe.

Doctors had to face various problems due to the manual record-keeping process. There was always a threat of damaging or losing data. This problem is solved with the help of EHRs. Moreover, its comparatively easier to transfer the details of a patient to another doctor.

Many applications are aided by an AI, capable of learning and developing on their own. The AI uses information uploaded in the database.

What are the benefits of technology in the healthcare sector?

The entry of tech in medicine can be considered a blessing in disguise for many doctors and patients. Some of them are mentioned below:

The beginning of telemedicine was marked by the accessibility of healthcare services for all the people. Imagine you live in a remote area, and you see a rash on your arm. All you need to do is click a picture and upload it along with your application symptoms. Then it will direct you to a proper doctor.

It helps people detect problems at an early stage so that doctors could stop the prognosis of a particular disease. It can also prove to be handy to figure out the possibility of new conditions and ways to tackle them.

People always fear that machines would replace them, and they could end up losing their jobs. Instead, you would require people that can guide you through the maze of systems and complex machinery. This situation, in turn, means more people would get hired.

Once you begin to bring a change in the world, youre bound to face some challenges. They help you to find loopholes in your products or services so that you can improve them. The developers are always vigilant regarding the ability of their device or software to function at full capacity.

A brief list of challenges are posing a threat to the advancement of the medical sector:

A persons medical records consist of much detailed personal information. If it falls into the wrong hands, it can cause unimaginable damage to the person. Moreover, some places are still using old tech, making it easier for hackers to get their hands on the precious data.

In most medical setups, you might find physicians that are experienced and accomplished in their fields. However, this experience comes from years of practice. So, at their given age, learning a complex skill can cause hindrance to the workflow. Even if they can get the hang of a tech piece, it might get replaced with another version.

Many hospitals and small scale clinics find it hard to keep up with the changes as new technology is quite expensive. Moreover, theres a chance that your vendor drastically stops making that particular product without any warnings. So, if that system stops working, then your entire workflow and structure might come crumbling down.

Any medical facility is filled with many machines that are used by different departments. With the EHR innovation, all of you need to do is scan the barcode, and every record would be digitalized. However, as astounding it sounds, it can be a bit more chaotic. Due to the lack of structure and organization of the data, bringing forth the information could be problematic.

As you know, people would keep searching for new ways to make your lives more comfortable and hassle-free. Its safe to say that youre now familiar with the techs involvement in medicine. Heres what more you can expect in the coming years.

The touch of reality makes augmented reality different from virtual reality. The ability to make speedy availability of data has paved the way for AR in the medicine market. It can be beneficial for students learning to be surgeons or physicians. As compared to a dummy or real body, you can better understand human anatomy with an AR.

Telehealth can be of aid for numerous purposes, but you still need to visit a hospital for surgery. Robots in operation theatre can cut down the chances of human error to a great extent. This improvement, in turn, decreases the pain and speeds up the recovery process. Moreover, it can also shield the doctors from all the tremendous amount of stress they bear.

The presence of nanotechnology inside someones body could be overwhelming to some people. However, what people fail to understand is that it can help us better understand complex issues like cancer or allergies. The primary role of nanomedicine is to detect, treat, and even restrain various diseases from spreading.

It has vast potential, from printing artificial limbs to creating blood vessels. Individual doctors are trying to perfect the art of printing actual human skin, which includes blood vessels. It can be a boon for people suffering from third-degree burns. Soon, you can also expect the pharmaceutical companies to print FDA approved 3-D drugs.

Read more:
Heres how healthcare industry is evolving with technology - AppleMagazine

A biopharma that uses gold to develop treatments for neurodegenerative diseases just got a little bit richer.

Clene Nanomedicine pulled in $42.5 million in a Series D financing round Wednesday, money which will go toward advancing its lead program through a Phase III platform trial in ALS and support Phase II trials in MS, Parkinsons disease and ALS. CEO Rob Etherington said that by the end of 2021, Clene will know whether or not the candidate, called CNM-Au8, will prove effective.

It will take us to the end of all these clinical endpoints, Etherington told Endpoints News. The exciting thing for us is that one asset could potentially be indicated to improve neurological function in MS, as well as ALS, and [though] Parkinsons is the slower program, this money is going to help us launch more completely that program.

CNM-Au8 is a liquid suspension of gold nanocrystals that catalyze intracellular biological reactions. Such catalyzation can lead to improvement in nerve cell survival, function, and communication. Chemically, the clean surfaces of the nanocrystals help normalize ATP production in cells, which is lacking in serious neurological diseases like ALS, CMO Robert Glanzman said.

Were providing bioenergy support to cells, Glanzman said. Theres a reason why we tend to get neurodegenerative diseases as we get older, and that is because as we age, theres a linear loss of bioenergetic capacity within neurons and what were doing is actually providing these neurons and other cells with free energy, essentially.

In terms of visible symptoms, Glanzman added that patients taking CNM-Au8 will see better strength, muscle mass and be able to speak, breathe and swallow more easily over a longer period of time.

Clenes Phase III study comes as it was selected to participate in the first-ever platform trial for ALS, which enrolled its first patients earlier this month. The trial compares three separate treatments for the disease, with UCBs zilucoplan and Biohavens verdiperstat joining CNM-Au8 at Harvard-backed Massachusetts General Hospital in testing 480 total patients.

Though delayed from a March start due to the Covid-19 pandemic, the platform trial aims to expedite the development of therapies for a disease that advances rapidly and that has few effective treatment options. Only riluzole, also known as Rilutek and OKed in 1995, shows any measurable effect on ALS patients, Etherington said.

Riluzole, which functionally is really the only drug that most people with ALS use, was originally approved to delay the need for tracheostomies to encourage breathing for an extra couple months, Etherington said. But it has a very modest effect generally. It is the standard of care, however, because its the only really markedly relevant drug thats been approved for ALS in this country. Theres a few others but most of them do very little.

Clene has two other programs in the pipeline, though neither have reached the clinic just yet. The first is a topical gel containing silver and zinc ions, with researchers looking at burn treatment, accelerated wound-healing and as an anti-infective. Theres also a gold-platinum therapeutic being studied for use in oncology, which is still in the initial in vitro stage.

The bottom line for Clene though is that finding a treatment option for the extremely difficult ALS indication becomes closer to reality, with a potentially huge impact on the field.

The way you and I move and can grasp things and can talk, all this fine motor movement we take for granted, Etherington said. An ALS patient loses these and this is exactly what we are studying.

Originally posted here:
Clene Nanomedicine, researching the use of gold atoms to slow ALS progression, nets $42.5M Series D - Endpoints News